Full Press Release Details
ASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years.
REGN
ASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years
Key Takeaway: ASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism